APGE Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $1.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.0% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Apogee Therapeutics, Inc.
Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need.
Sector
Healthcare
Industry
Biotechnology